Table 4.

Clinical and laboratory characteristics of non-ST elevation myocardial infarction (non-STEMI), stable angina (SA) patients divided on the basis of % change in NK cells over 12 months.

	‘Increase group’	‘Non-increase group’	P-value
	Upper tertile (n = 14)	Lower tertile (n = 14)
Age, years	61 (58–71)	66 (58–72)	n.s.
Female (%)	26	26	n.s.
Smokers (%)	21	21	n.s.
Waist circumference (cm)	94 (90–104)	104 (97–110)	0·036
Hypertension (%)	64	64	n.s.
Diabetes (%)	0	14	n.s.
ACS as index event, %	43	29	n.s.
Prior history of CAD, %	14	36	n.s.
Normal left ventricular systolic function (%)	86	71	n.s.
Left ventricular systolic dysfunction, mild/moderate, %	7/7	29/0	n.s.
Statin treatment, %
Day 1	50	64	n.s.
3 months	86	93	n.s.
CMV IgG seropositive %	71	86	n.s.
LDL cholesterol, mmol/l
Day 1	3·6 (2·6–4·2)	2·5 (2·3–3·4)	n.s.
3 months	2·4 (1·9–3·2)	2·1 (1·6–2·4)	n.s.
HDL cholesterol, mmol/l
Day 1	1·4 (1·2–1·5)	1·2 (1·0–1·5)	n.s.
3 months	1·4 (1·2–1·6)	1·2 (1·0–1·4)	n.s.
Triglycerides, mmol/l
Day 1	1·3 (1·0–1·8)	1·6 (1·4–2·6)	0·038
3 months	1·0 (0·9–1·3)	1·5 (1·2–2·0)	0·005
Remnant cholesterol, mmol/l
Day 1	0·7 (0·5–1·1)	0·8 (0·6–1·3)	n.s.
3 months	0·5 (0·4–0·7)	0·7 (0·5–1·6)	n.s.
Cystatin C, mg/l
Day 1	1·2 (0·9–1·3)	1·1 (1·0–1·2)	n.s.
3 months	1·1 (0·9–1·3)	1·1 (1·1–1·3)	n.s.
IL-6, pg/ml
Day 1	3·8 (1·7–5·3)	4·3 (2·3–6·7)	n.s.
3 months	1·7 (1·0–2·3)	3·0 (2·4–4·0)	0·003

Values are given as medians (interquartile range). P-value refers to Mann–Whitney test for ordinal data and χ² test for nominal data, comparing ‘increase group and ‘non-increase group’. ACS: acute coronary syndrome; CAD: coronary artery disease; CMV: cytomegalovirus; LDL: low-density lipoprotein; HDL: high-density lipoprotein; IL: interleukin; Ig: immunoglobulin.